个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Wei Qi[1,2] * ; Deng Taibing[3] * ; Wu Junhua[4] * ; Zeng Hao[1,2] ; Qi Chang[1,2] ; Tan Sihan[1,2] ; Zhang Yuanyuan[1,2] ; Huang Qin[1,2] ; Pu Xin[1,2] ; Xu Weiguo[4] ; Li Weimin[1] ; Tian Panwen[1,2] ; Li Yalun[1,2] ;
机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China [3]Pulmonary and Critical Care Medicine, Guang ’an People’s Hospital, Guang ’an, China [4]Respiratory and Critical Care Medicine, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China
出处：
DOI： 10.1186/s12885-024-12173-1

关键词： Non-small cell lung cancer Malignant pleural effusion Immunotherapy Chemotherapy Efficacy

摘要：
Immune checkpoint inhibitors (ICI) combined with chemotherapy are efficacious for treating advanced non-small cell lung cancer (NSCLC); however, the effectiveness of this approach in the malignant pleural effusion (MPE) population is unclear. This study evaluated ICI plus chemotherapy in NSCLC patients with MPE.Patients from 3 centers in China with NSCLC and MPE who received ICI plus chemotherapy (ICI Plus Chemo) or chemotherapy alone (Chemo) between December 2014 and June 2023 were enrolled. Clinical outcomes and adverse events (AEs) were compared.Of 155 eligible patients, the median age was 61.0 years old. Males and never-smokers accounted for 73.5% and 39.4%, respectively. Fifty-seven and 98 patients received ICI Plus Chemo or Chemo, respectively. With a median study follow-up of 10.8 months, progression-free survival (PFS) was significantly longer with ICI Plus Chemo than with Chemo (median PFS: 7.4 versus 5.7 months; HR = 0.594 [95% CI: 0.403-0.874], P = 0.008). Median overall survival (OS) did not differ between groups (ICI Plus Chemo: 34.2 versus Chemo: 28.3 months; HR = 0.746 [95% CI: 0.420-1.325], P = 0.317). The most common grade 3 or worse AEs included decreased neutrophil count (3 [5.3%] patients in the ICI Plus Chemo group vs. 5 [5.1%] patients in the Chemo group) and decreased hemoglobin (3 [5.3%] versus 10 [10.2%]).In patients with untreated NSCLC with MPE, ICI plus chemotherapy resulted in significantly longer PFS than chemotherapy and had a manageable tolerability profile, but the effect on OS may be limited.© 2024. The Author(s).

基金：
National Natural Science Foundation of China (No. 82072598 to P Tian, 92159302 to W Li), Science and Technology Project of Sichuan, China (No. 2022ZDZX0018 to W Li), and 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University, China (No. ZYJC21052 to P Tian, No. ZYGD22009 to W Li).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
推荐引用方式(GB/T 7714)：
Wei Qi,Deng Taibing,Wu Junhua,et al.Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study[J].BMC Cancer.2024,24(1):393.doi:10.1186/s12885-024-12173-1.
APA：
Wei Qi,Deng Taibing,Wu Junhua,Zeng Hao,Qi Chang...&Li Yalun.(2024).Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.BMC Cancer,24,(1)
MLA：
Wei Qi,et al."Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study".BMC Cancer 24..1(2024):393

相关文献

[1]Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion [2]Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. [3]The role of angiogenesis in malignant pleural effusion: from basic research to clinical application [4]The role of angiogenesis in malignant pleural effusion: from basic research to clinical application [5]Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review). [6]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [7]Patients with Malignant Pleural Effusion who Succeeded Pleurodesis have a Longer Survival Rate A 10-year Follow-Up [8]Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis [9]Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis [10]Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号